Bone loss in pediatric renal transplant recipients.
The factors that affect bone mineral density (BMD) and the long term progress of BMD after transplantation in children is still unknown. Therefore we performed a cross-sectional study to determine BMD in 83 recipients who received living renal allotransplants in Mansoura Urology & Nephrology Center between 1981 and 2001 (mean age at transplantation 13.2 +/- 3.1 years) by dual energy x-ray absorptiometry at various time intervals up to 16 years after transplantation (mean duration after transplantation was 48 +/- 34 months, range 6-192 months). The Z-score for lumbar spine was -2.28 +/- 2.06 and -1.44 +/- 1.44 for the total body. Osteopenia/osteoporosis were present in about two thirds of our kidney transplant recipients. The significant predictors for osteopenia/osteoporosis by univariate analysis were cyclosporine based immunosuppression, the cumulative steroid dose/m2 surface area, graft dysfunction and the urinary deoxypyridinoline. Using logistic regression analysis the cumulative steroid dose/m2 surface area and the urinary deoxypyridinoline were the major significant predictors for bone loss.
el-Husseini
A A
AA
Mansoura Urology & Nephrology Center, Mansoura University, Mansoura, Egypt.
el-Agroudy
A E
AE
Sobh
M A
MA
Ghoneim
M A
MA
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000453:epidemiology* / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D004534:Egypt / Q000453:epidemiology; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007676:Kidney Failure, Chronic / Q000150:complications / Q000601:surgery / Q000628:therapy; D016030:Kidney Transplantation; D016014:Linear Models; D008297:Male; D010024:Osteoporosis / Q000453:epidemiology* / Q000209:etiology; D011183:Postoperative Complications / Q000453:epidemiology* / Q000209:etiology; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D003404:Creatinine